HU CFAR investigators have a long history of high impact contributions stemming from bench-to-bedside research. The CFAR Clinical Core activities have been absolutely essential to the success of these HIV/AIDS research efforts at Harvard by providing the clinical infrastructure, clinical samples and clinical information critical to these studies;these components of translational research are either not funded or are only inadequately funded by other support mechanisms. With the expansion to a Harvard-wide CFAR, the Clinical Core continues to set new goals and modify its mission to be maximally responsive to its members, in particular now with an expanding international focus to this Core. To address ongoing needs of HU CFAR investigators, we now propose to accomplish the following specific aims: ? To provide infrastructure support for HU CFAR investigators conducting clinical and basic science research related to HIV/AIDS and its associated opportunistic infections, domestically and internationally. ? To develop and provide access to databases and clinical specimen repositories from wellcharacterized HIV-infected populations domestically and internationally. ? To support educational and outreach programs designed to facilitate clinical and translational research at HU and at international sites associated with HU CFAR investigators.
The improvement in the care of people living with HIV/AIDS has been made possible because of research into how HIV causes disease and how to treat the virus. The Clinical Core of the CFAR will provide support for researchers who are studying how to improve the care of patients with HIV, both in the U.S. and around the world.
|Ballandras-Colas, Allison; Brown, Monica; Cook, Nicola J et al. (2016) Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function. Nature 530:358-61|
|Jain, Sachin; Oldenburg, Catherine E; Mimiaga, Matthew J et al. (2016) High Levels of Concomitant Behavioral Health Disorders Among Patients Presenting for HIV Non-occupational Post-exposure Prophylaxis at a Boston Community Health Center Between 1997 and 2013. AIDS Behav 20:1556-63|
|Sunshine, Sara; Kirchner, Rory; Amr, Sami S et al. (2016) HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol 90:4511-9|
|Krakower, Douglas S; Mayer, Kenneth H (2016) Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough? J Infect Dis 214:983-5|
|Mayer, Kenneth H; Krakower, Douglas S; Boswell, Stephen L (2016) Antiretroviral Preexposure Prophylaxis: Opportunities and Challenges for Primary Care Physicians. JAMA 315:867-8|
|Saito, Akatsuki; Henning, Matthew S; Serrao, Erik et al. (2016) Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo. J Virol 90:6918-35|
|Krakower, Douglas S; Maloney, Kevin M; Grasso, Chris et al. (2016) Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. J Int AIDS Soc 19:21165|
|Brown, Carolyn A; Suneja, Gita; Tapela, Neo et al. (2016) Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist 21:731-8|
|McDavitt, Bryce; Bogart, Laura M; Mutchler, Matt G et al. (2016) Dissemination as Dialogue: Building Trust and Sharing Research Findings Through Community Engagement. Prev Chronic Dis 13:E38|
|Gandhi, Rajesh T; Kwon, Douglas S; Macklin, Eric A et al. (2016) Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 71:246-53|
Showing the most recent 10 out of 844 publications